A deformylase inhibitor expands therapeutic options for Lyme disease

Kim Lewis1, Pankaj Patil2, Hsin-Wen Liang2

  • 1Northeastern University.

Research Square
|May 18, 2026
PubMed

Insights

A new drug, forazemin, shows potent activity against Lyme disease bacteria. It effectively treats Lyme borreliosis and neuroborreliosis in mice while preserving gut microbiome health, offering a promising alternative to current treatments.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Lyme disease incidence is increasing globally, posing a significant public health challenge.
  • Current treatments like doxycycline and ceftriaxone have limitations, including gut microbiome disruption, resistance development, and suboptimal efficacy against neuroborreliosis.

Purpose of the Study:

  • To evaluate forazemin (BB-83698), a novel peptide deformylase inhibitor, as a potential treatment for Lyme disease.
  • To assess forazemin's efficacy and safety in preclinical models of Lyme borreliosis and neuroborreliosis.

Main Methods:

  • Forazemin's bactericidal activity against diverse Borrelia species was tested.
  • Efficacy was evaluated in murine models of Lyme borreliosis and neuroborreliosis, including tick-bite prophylaxis.
  • Impact on gut microbiome diversity and beneficial symbionts was assessed.

Main Results:

  • Forazemin demonstrated potent and selective bactericidal activity against Borrelia spirochaetes by inhibiting protein synthesis.
  • Oral forazemin cleared infection in murine models of Lyme borreliosis and neuroborreliosis with short dosing regimens.
  • Forazemin outperformed doxycycline in tick-bite prophylaxis and preserved gut microbiome diversity.

Conclusions:

  • Forazemin is a promising orally bioavailable drug candidate for treating and preventing Lyme disease.
  • Its targeted mechanism and favorable microbiome profile offer advantages over existing therapies.
  • Further development of forazemin is warranted for Lyme disease management.

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...